For the quarter ending 2025-09-30, AMRX had $154,735K increase in cash & cash equivalents over the period. $106,152K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 18,132 | 60,228 |
| Depreciation and amortization | 54,073 | 120,272 |
| Unrealized foreign currency gain | -3,207 | 11,813 |
| Amortization of debt issuance costs and discount | 5,030 | 13,686 |
| Reclassification of cash flow hedge | -4,163 | 5,876 |
| Loss on refinancing | -31,365 | - |
| Intangible asset impairment charges | 22,784 | 0 |
| Stock-based compensation | 8,219 | 15,532 |
| Inventory provision | 20,894 | 38,432 |
| Other operating charges and credits, net | -1,321 | -2,254 |
| Trade accounts receivable, net | 77,613 | 32,615 |
| Inventories | 30,807 | 36,039 |
| Prepaid expenses, other current assets and other assets | 10,158 | 10,015 |
| Related party receivables | -278 | 1,108 |
| Accounts payable, accrued expenses and other liabilities | 69,748 | -67,004 |
| Related party payables | -2,186 | 5,293 |
| Net cash provided by operating activities | 118,450 | 91,227 |
| Purchases of property, plant and equipment | 12,298 | 35,992 |
| Acquisition of intangible assets | 7,414 | 5,100 |
| Deposits for future acquisition of property, plant and equipment | 2,752 | 4,632 |
| Proceeds from sale of property, plant and equipment | 0 | 1,379 |
| Proceeds from sale of subsidiary | 0 | 0 |
| Net cash used in investing activities | -22,464 | -44,345 |
| Proceeds from issuance of debt | 2,694,750 | - |
| Payments of principal on debt, revolving credit facilities, financing leases and other | 2,554,308 | 251,076 |
| Payments of deferred financing and refinancing costs | 73,228 | 1,745 |
| Borrowings on revolving credit facilities | 0 | 218,000 |
| Proceeds from exercise of stock options | 653 | 754 |
| Employee payroll tax withholding on restricted stock unit and performance stock unit vesting | 129 | 21,828 |
| Tax and other distributions to non-controlling interests | 13,867 | 24,958 |
| Payment of principal on notes payable - related party | 0 | 0 |
| Proceeds from alliance party | 5,572 | - |
| Net cash used in financing activities | 59,443 | -80,853 |
| Effect of foreign exchange rate on cash | -694 | -777 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 154,735 | -34,748 |
| Cash and cash equivalents at beginning of period | 118,420 | - |
| Cash and cash equivalents at end of period | 238,407 | - |
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX)